drugset / Trial / NCT07597629

A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer

NCT07597629

Phase 2 Recruiting 36 enrolled CSPC Megalith Biopharmaceutical Co.,Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.

Timeline

Start
2026-05-25
Primary completion
2027-11-30
Completion
2029-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SYS6023 Other / unclassified Intravenous
Background KN026 Monoclonal antibody Intravenous

Indications